SiBone (NASDAQ:SIBN) Insider Anthony Recupero Sells 3,677 Shares

SiBone (NASDAQ:SIBN) insider Anthony Recupero sold 3,677 shares of the stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $19.62, for a total value of $72,142.74. Following the completion of the transaction, the insider owned 264,467 shares of the company’s stock, valued at $5,188,842.54. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

SiBone Trading Up 2.2%

Shares of SiBone stock traded up $0.43 on Tuesday, hitting $20.40. The stock had a trading volume of 412,471 shares, compared to its average volume of 464,090. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97. SiBone has a twelve month low of $12.49 and a twelve month high of $21.07. The stock has a 50 day moving average of $18.49 and a 200 day moving average of $17.01. The firm has a market capitalization of $885.18 million, a P/E ratio of -40.00 and a beta of 0.69.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. The company had revenue of $48.66 million for the quarter, compared to analysts’ expectations of $46.67 million. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. Sell-side analysts expect that SiBone will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SiBone

A number of large investors have recently modified their holdings of SIBN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in SiBone by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after buying an additional 1,053 shares during the last quarter. Tudor Investment Corp ET AL grew its holdings in shares of SiBone by 0.8% during the third quarter. Tudor Investment Corp ET AL now owns 258,032 shares of the company’s stock valued at $3,798,000 after buying an additional 1,968 shares during the last quarter. Rhumbline Advisers increased its position in shares of SiBone by 3.6% during the first quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock worth $838,000 after acquiring an additional 2,100 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of SiBone by 8.3% in the 3rd quarter. Franklin Resources Inc. now owns 29,018 shares of the company’s stock worth $427,000 after acquiring an additional 2,228 shares during the last quarter. Finally, State of Alaska Department of Revenue bought a new position in SiBone in the 3rd quarter valued at about $39,000. 98.11% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on SIBN shares. Canaccord Genuity Group upped their price objective on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Needham & Company LLC upped their price target on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Morgan Stanley increased their price target on SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Finally, Truist Financial raised their target price on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $25.00.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.